Ramón y Cajal University Hospital, Medical Oncology Department, IRYCIS, CIBERONIC, Alcala University, Madrid, Spain.
Digestive Molecular Clinical Oncology Unit, University of Verona, Verona, Italy.
Future Oncol. 2021 May;17(15):1843-1854. doi: 10.2217/fon-2020-0749. Epub 2021 Mar 5.
To survey European physicians managing patients with metastatic pancreatic ductal adenocarcinoma (PDAC) and understand differences in baseline characteristics, diagnostic methods, symptoms and co-morbidities. Patient record inclusion criteria were: ≥18 years old, metastatic PDAC diagnosis and completion of first-line treatment between July 2014 and January 2016. Records were grouped by patient age, gender and primary tumor location. Records (n = 2565) were collected from nine countries. Baseline characteristics varied between subgroups. Computed tomography was the most frequently used diagnostic technique. Symptoms at diagnosis included abdominal and/or mid-back pain (72% of patients) and weight loss (61.5%). Co-morbidities varied with patient age. Greater awareness of symptoms, diagnostic methods and co-morbidities present at PDAC diagnosis may support better patient management decisions.
调查欧洲医生对转移性胰腺导管腺癌(PDAC)患者的治疗管理情况,并了解基线特征、诊断方法、症状和合并症方面的差异。患者病历纳入标准为:年龄≥18 岁,转移性 PDAC 诊断,2014 年 7 月至 2016 年 1 月期间完成一线治疗。病历按患者年龄、性别和原发肿瘤位置分组。从 9 个国家收集了病历(n=2565)。亚组之间的基线特征存在差异。计算机断层扫描是最常用的诊断技术。诊断时的症状包括腹部和/或中背部疼痛(72%的患者)和体重减轻(61.5%)。合并症随患者年龄而变化。提高对 PDAC 诊断时出现的症状、诊断方法和合并症的认识,可能有助于做出更好的患者管理决策。